Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market

Fineline Cube Mar 13, 2026
Company Deals

APC Group and Youcare Pharmaceutical Forge Strategic Partnership – Global Distribution Alliance Targets China-India Pharma Collaboratio

Fineline Cube Mar 13, 2026
Company Deals

WuXi Biologics Partners with Earendil Labs – Integrated CDMO Services for Bispecific Antibodies and ADCs Targeting Autoimmune and Oncology Indications

Fineline Cube Mar 13, 2026
Company Deals

Everest Medicines Reports Positive Phase IIa Data for VIS-101 – Dual VEGF-A/Ang-2 Inhibitor Shows Best-in-Class Potential in wAMD

Fineline Cube Mar 13, 2026
Company Deals

Luye Pharma Signs Strategic Partnership with Sinopharm – Mimeixin Distribution Deal Targets China’s Severe Pain Market

Fineline Cube Mar 13, 2026
Policy / Regulatory

China’s Basic Medical Insurance Covers 1.33 Billion in 2025 – NHSA Reports RMB 3.6 Trillion Fund Inflows, 114 New Drugs Added to NRDL

Fineline Cube Mar 16, 2026
Company Drug

Hengrui’s Irinotecan Liposome (II) Wins NMPA Phase II Approval – Adjuvant Pancreatic Cancer Study vs. Gemcitabine/Capecitabine

Fineline Cube Mar 16, 2026
Company Drug

3SBio Wins NMPA Approval for Eltrombopag Generic – TPO-RA Copycat Targets Novartis’ Revolade in China ITP/SAA Market

Fineline Cube Mar 16, 2026
Company Deals

Lion TCR Secures RMB 300 Million in Series B2 Financing to Advance Clinical Studies and Facility Construction

Fineline Cube Jun 27, 2023

Singapore-based clinical-stage biotechnology company Lion TCR has announced the successful completion of its Series B2...

Company Drug

LianBio’s Mavacamten Receives Priority Review Status from China’s CDE for oHCM Treatment

Fineline Cube Jun 27, 2023

The Center for Drug Evaluation (CDE) has indicated on its website that China-based biotech firm...

Company Drug

CSPC Pharmaceutical Group Gets NMPA Approval for JMT203 Cancer Cachexia Clinical Study

Fineline Cube Jun 27, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...

Policy / Regulatory

NMPA Releases 69th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Jun 27, 2023

The National Medical Products Administration (NMPA) has released the 69th batch of reference drugs for...

Company Deals

BDgene Technology Secures Over RMB 200 Million in Series B Financing Led by Lapam Capital

Fineline Cube Jun 27, 2023

Gene therapy specialist Shanghai BDgene Technology Co., Ltd has successfully raised over RMB 200 million...

Company Deals

WuXi Biologics Partners with Pharmadule Morimatsu AB for CRDMO Expansion in Singapore

Fineline Cube Jun 27, 2023

China-based WuXi Biologics (HKG: 2269) has announced a strategic partnership with Sweden-headquartered Pharmadule Morimatsu AB...

Company Drug

CStone Pharmaceuticals’ Gavreto Approved for First-Line RET Fusion-Positive NSCLC Treatment in China

Fineline Cube Jun 27, 2023

China-based CStone Pharmaceuticals (HKG: 2616) has announced that the National Medical Products Administration (NMPA) of...

Company Drug

CSPC Pharmaceutical’s Biosimilar Omalizumab Accepted for Review by China’s NMPA

Fineline Cube Jun 27, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that the National Medical Products Administration...

Company Drug

Henlius Biotech’s HLX13 Biosimilar Gets NMPA Approval for Liver Cancer Clinical Trial

Fineline Cube Jun 27, 2023

Shanghai Henlius Biotech, Inc (HKG: 2696) has announced receiving clinical trial approval from the National...

Company Drug

Chia Tai Tianqing Launches First Batch of F-627 for Neutropenia Treatment in China

Fineline Cube Jun 27, 2023

China-based Chia Tai Tianqing has announced the first batch prescriptions in China for its efbemalenograstim...

Company Drug

Jiangsu Kanion Pharmaceutical Gets FDA Approval for KYS202002A Clinical Study in Multiple Myeloma

Fineline Cube Jun 27, 2023

China-based Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced receiving the green light from...

Company Deals

Mega Lifesciences Secures Exclusive Rights for Bio-Thera’s Bevacizumab Biosimilar in Indonesia

Fineline Cube Jun 27, 2023

Thailand-based Mega Lifesciences (BKK: MEGA) has announced an in-licensing agreement with China-based Bio-Thera Solutions (SHA:...

Company Drug

Jiangsu Hengrui’s Dalpiciclib Approved for Initial Therapy in HR+, HER2- Breast Cancer

Fineline Cube Jun 27, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Drug

Fosun Kite’s Yescarta Gains NMPA Approval for Refractory Large B-Cell Lymphoma

Fineline Cube Jun 27, 2023

China-based Fosun Kite Biotechnology Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co.,...

Company Drug

Ascletis Pharma’s ASC42 Showcased in Combination Therapy for Chronic Hepatitis B at EASL 2023

Fineline Cube Jun 26, 2023

China-based Ascletis Pharma Inc. (HKG: 1672) announced the poster presentation of ASC42, a novel farnesoid...

Company Deals Policy / Regulatory

Sinopharm Expands Partnership with Guizhou Government to Boost Health Industry

Fineline Cube Jun 26, 2023

China National Pharmaceutical Group Corporation (Sinopharm, HKG: 1099) has announced a strengthened partnership with the...

Company Deals

Coherent Biopharma and C-Ray Therapeutics Partner to Advance Peptide-Drug Conjugate Development

Fineline Cube Jun 26, 2023

China-based Coherent Biopharma and C-Ray Therapeutics have announced a strategic partnership to delve into the...

Company Drug

CANbridge Pharmaceuticals Reports Positive Phase Ib Results for Omoprubart in PNH Treatment

Fineline Cube Jun 26, 2023

China-based rare disease firm CANbridge Pharmaceuticals Inc., (HKG: 1228) has published the preliminary results of...

Company Medical Device

Sino Medical Sciences Technology Secures FDA Thailand Approval for NC Rockstar Balloon Catheter

Fineline Cube Jun 26, 2023

China-based Sino Medical Sciences Technology Inc., (SHA: 688108) has announced that it has received market...

Company Drug

Haisco Pharmaceutical’s HSK31679 Receives Clinical Trial Approval for NASH Treatment

Fineline Cube Jun 26, 2023

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its in-house developed Category...

Posts pagination

1 … 479 480 481 … 634

Recent updates

  • Hengrui’s Irinotecan Liposome (II) Wins NMPA Phase II Approval – Adjuvant Pancreatic Cancer Study vs. Gemcitabine/Capecitabine
  • 3SBio Wins NMPA Approval for Eltrombopag Generic – TPO-RA Copycat Targets Novartis’ Revolade in China ITP/SAA Market
  • Chipscreen Biosciences’ CS08399 Wins NMPA Approval – PRMT5-MTA Inhibitor Targets MTAP-Deficient Solid Tumors and Lymphomas
  • China’s Basic Medical Insurance Covers 1.33 Billion in 2025 – NHSA Reports RMB 3.6 Trillion Fund Inflows, 114 New Drugs Added to NRDL
  • Novartis’ Cosentyx Wins FDA Pediatric Approval – Only IL-17A Inhibitor for Hidradenitis Suppurativa in Adolescents 12+
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui’s Irinotecan Liposome (II) Wins NMPA Phase II Approval – Adjuvant Pancreatic Cancer Study vs. Gemcitabine/Capecitabine

Company Drug

3SBio Wins NMPA Approval for Eltrombopag Generic – TPO-RA Copycat Targets Novartis’ Revolade in China ITP/SAA Market

Company Drug

Chipscreen Biosciences’ CS08399 Wins NMPA Approval – PRMT5-MTA Inhibitor Targets MTAP-Deficient Solid Tumors and Lymphomas

Policy / Regulatory

China’s Basic Medical Insurance Covers 1.33 Billion in 2025 – NHSA Reports RMB 3.6 Trillion Fund Inflows, 114 New Drugs Added to NRDL

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.